Table 1 Baseline characteristics of all 138 patients at the initiation and cessation of lamivudine treatment
Characteristics at the initiation of LAM | All patients (n = 138) | Initial HBeAg- positive (n = 102) | Initial HBeAg- negative (n = 36) | P-value* |
|---|---|---|---|---|
Age (years) | 39 (16-79) | 37 (16-67) | 45 (25-79) | 0.001 |
Sex (male), n (%) | 82 (59.4) | 59 (57.8) | 23 (63.9) | 0.560 |
ALT (IU/L) | 204 (41-1476) | 214 (41-994) | 164 (42-1476) | 0.864 |
Albumin (g/dL) | 3.9 (1.8-4.6) | 3.9 (1.8-4.6) | 4.0 (2.3-4.4) | 0.664 |
Total bilirubin (mg/dL) | 1.2 (0.4-22.1) | 1.2 (0.4-22.0) | 1.2 (0.5-22.1) | 0.430 |
HBV DNA (Log10 copies/mL) | 7.4 (5.0-10.0) | 7.5 (5.0-10.0) | 7.4 (5.4-9.1) | 0.877 |
Liver cirrhosis | 17 (12.3) | 9 (8.8) | 8 (22.2) | 0.040 |
Characteristics at cessation of LAM | n =  138 | n =  102 | n =  36 | P -value |
Age (years) | 43 (19-82) | 41 (19-69) | 48 (28-82) | 0.001 |
ALT (IU/L) | 18 (5-38) | 19 (7-38) | 18 (5-38) | 0.696 |
Albumin (g/dL) | 4.1 (2.8-4.7) | 4.1 (2.8-4.7) | 4.1 (3.4-4.4) | 0.518 |
Total bilirubin (mg/dL) | 1.1 (0.5-1.8) | 1.1 (0.6-1.8) | 1.1 (0.5-1.2.0) | 0.297 |
HBV DNA (copies/mL), n (%)†|  |  |  | 0.006 |
   <50 | 68 (49.3) | 42 (41.2) | 26 (72.2) |  |
   50-104 | 48 (34.8) | 41 (40.2) | 7 (19.4) |  |
   104 ≤ | 22 (15.9) | 19 (18.6) | 3 (8.3) |  |
HBeAg loss/seroconversion, n (%) | NA | 82 (80.4) | NA | Â |
Treatment duration (month) | 35.5 (13-98) | 35.6 (13-98) | 35.1 (14-80) | 0.333 |